Archive

The 503A vote is about compounding eligibility, not approved treatments.

One sits in metabolic signaling. The other sits in GH-axis research.

The number matters less than the trend.

The smarter angle is not beauty. It is repair biology.

The smarter question is not “should I take it?” It’s “what system is under pressure?”